Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Inventory (2023 - 2025)

Krystal Biotech (KRYS) has disclosed Change in Inventory for 3 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Change in Inventory fell 83.78% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.3 million through Dec 2025, down 47.21% year-over-year, with the annual reading at $6.3 million for FY2025, 47.21% down from the prior year.
  • Change in Inventory hit $1.1 million in Q4 2025 for Krystal Biotech, down from $4.7 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $6.5 million in Q4 2024 to a low of -$880000.0 in Q2 2025.
  • Historically, Change in Inventory has averaged $2.1 million across 3 years, with a median of $1.4 million in 2025.
  • Biggest YoY gain for Change in Inventory was 1225.41% in 2024; the steepest drop was 158.5% in 2024.
  • Year by year, Change in Inventory stood at $492000.0 in 2023, then skyrocketed by 1225.41% to $6.5 million in 2024, then plummeted by 83.78% to $1.1 million in 2025.
  • Business Quant data shows Change in Inventory for KRYS at $1.1 million in Q4 2025, $4.7 million in Q3 2025, and -$880000.0 in Q2 2025.